Harnessing pyrimidine as a building block for histone deacetylase inhibitors.

Autor:	Badran MM; Department of Medicinal Chemistry, Faculty of Pharmacy, South Valley University, Qena, Egypt.; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.; Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan., Abbas SH; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt., Fujita M; Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan., Abdel-Aziz M; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia, Egypt.
Jazyk:	angličtina
Zdroj:	Archiv der Pharmazie [Arch Pharm (Weinheim)] 2023 Oct; Vol. 356 (10), pp. e2300208. Date of Electronic Publication: 2023 Jul 18.
DOI:	10.1002/ardp.202300208
Abstrakt:	Histone deacetylase (HDAC) inhibitors are well-established multifaceted bioactive agents against tumors and neurodegenerative disorders. Pyrimidine and its fused and substituted derivatives were employed as a surface recognition moiety of HDAC inhibitors. De facto, the literature was loaded with different success stories of pyrimidine-based HDAC inhibitors that garnered much interest. Provoked by our continuous interest in HDAC inhibitors, we summarized and elaborated on the successful harnessing of the pyrimidine scaffold in this regard. Furthermore, we dissect our perspective that may guide medicinal chemists for an effective future design of more active chemotherapeutic agents with potential clinical applications. (© 2023 Deutsche Pharmazeutische Gesellschaft.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text